Description
Palazestrant is an investigational medication currently being studied in clinical trials. It is being investigated for its potential use in certain types of cancer, including breast cancer. In the context of colorectal cancer, it is being studied in combination with another investigational drug called OP-3136 in a Phase 1 trial (NCT06784193). This trial is evaluating the safety and tolerability of the combination in patients with advanced or metastatic solid tumors, including colorectal cancer. Palazestrant is being studied specifically in patients whose tumors have a HER2 mutation. It is important to note that this drug is still in early-phase clinical development, and its effectiveness and safety specifically for colorectal cancer are still under investigation.
Mechanism of Action
Palazestrant is being studied as a selective estrogen receptor degrader (SERD). It works by binding to the estrogen receptor (ER) and causing it to break down, which may help to stop the growth of cancer cells that rely on estrogen signaling. In the clinical trial context, it is being combined with OP-3136, which is a lysine acetyltransferases 6A and 6B (KAT6A/B) inhibitor. The specific mechanism of action of this combination in colorectal cancer is being investigated.
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.